Allergies Clinical Development Generic Pharmaceutical Manufacturing 
XTalks
AUGUST 2, 2023
is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion the drug generated in 2021. every eight weeks for the 90 mg dose, according to the manufacturer. billion in 2022, a 23.43
The Pharma Data
DECEMBER 23, 2020
During this global health crisis response, we must establish partners with the strongest capabilities, like Aurobindo, to expand the manufacturing and delivery of our vaccine. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612.
The Pharma Data
DECEMBER 23, 2020
24, 2020 /PRNewswire/ — COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate. .
Expert insights. Personalized for you.
98 
Let's personalize your content